Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home PEPSE for HIV Prevention in High Risk Men
NCT04965662Phase 4Completed
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Jan 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of maraviroc in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Number of hours from HIV risk exposure to PEPSE at 48 weeks. Started Jan 2018; status: completed.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04965662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965662.